Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

4d Molecular Therapeutics In (FDMT)

146 + Investors. Track Smart Money conviction in FDMT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -2
Streak
1Q ▼
Buyers last Q
46%

Smart Money Signals — FDMT

Based on 147 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their FDMT positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (99% of max)

99% of all-time peak
147 hedge funds hold FDMT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +20% more funds vs a year ago

fund count last 6Q
+24 new funds entered over the past year (+20% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟠

More sellers than buyers — 46% buying

66 buying79 selling
Last quarter: 79 funds reduced or exited vs 66 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-6 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 17 → 30 → 32 → 26. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 31% medium ■ 22% new
69 out of 147 hedge funds have held FDMT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Price up while funds trimmed (+11% value, -11% shares)

Value
+10%
Shares
-10%
Last quarter: total value of institutional FDMT holdings rose +11% even though funds reduced share count by 11%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
📈

Growing discovery — still being found

18 → 17 → 30 → 32 → 26 new funds/Q
New funds entering each quarter: 17 → 30 → 32 → 26. A growing number of institutions are discovering FDMT each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 57% veterans vs 27% newcomers

■ 57% veterans ■ 16% 1-2yr ■ 27% new
Entry-cohort mix of 153 holders: 87 (57%) are 2+ year veterans, 25 entered 1–2 years ago, and 41 (27%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds
37 of 147 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — FDMT

In 2026 Q1, 66 hedge funds were net buyers of FDMT (26 opened a new position, 40 added to an existing one), while 79 reduced or exited (51 trimmed, 28 sold completely) — a 46% buyer ratio, indicating roughly balanced activity. 38% of total institutional value in FDMT is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -2 funds (more exits than new entries). Total institutional holders: 147.

Hedge Fund Ownership: FDMT

How many hedge funds hold FDMT — quarterly history vs. share price
Quarterly hedge fund ownership of FDMT vs. share price

Market Analysis: FDMT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: FDMT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy 4d Molecular Therapeutics In (FDMT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much FDMT has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
FDMT
-5.2%
XLV
+4.9%

FDMT outperformed XLV by -10.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
FDMT
-3.5%
XLV
+6.0%

Since the filing became public, FDMT outperformed XLV by -9.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

15 top-rated funds 2 high-conviction
Consensus
5.2
/ 10
breadth
×
Elite
2.2
/ 10
conviction
Hedge Fund Positioning: FDMT
146 + Investors

Track Smart Money conviction in FDMT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 146 149 -2.01%
13F Shares 48M 54M -10.54%
Total Value $444M $401M 10.76%
New Positions 25 32 -7
Increased Positions 39 58 -19
Closed Positions 28 12 +16
Reduced Positions 49 35 +14
Total Calls 3 3 -
Total Puts 3 2 50.0%
PUT/CALL Ratio 1.0 0.67 Neutral

Statistics: FDMT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

146 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in FDMT. Verified SEC 13F-HR filings.

QUARTER:
Top 25 FDMT holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Trails Edge Capital Partners, LP 2.78% 1,302,917 $12.1M
2 Novo Holdings A/S 2.75% 3,650,737 $34.0M
3 Propel Bio Management, LLC 2.26% 380,420 $3.6M
4 Peapod Lane Capital LLC 1.81% 241,480 $2.2M
5 Acuta Capital Partners, LLC 1.59% 242,255 $2.3M
6 Bvf Inc/Il 0.85% 2,879,289 $26.8M
7 Exome Asset Management LLC 0.63% 130,564 $1.2M
8 Parkman Healthcare Partners LLC 0.50% 522,577 $4.9M
9 Ra Capital Management, L.P. 0.50% 5,049,779 $47.0M
10 Armistice Capital, LLC 0.33% 2,000,000 $18.6M
11 Privium Fund Management B.V. 0.33% 170,256 $1.6M
12 Rangeley Capital, LLC 0.28% 31,465 $293K
13 Evergreen Quality Fund GP, Ltd. 0.20% 951,474 $8.9M
14 Opaleye Management Inc. 0.14% 112,291 $1.0M
15 Burkehill Global Management, LP 0.13% 275,000 $2.6M
16 Peloton Wealth Strategists 0.09% 25,000 $233K
17 Landing Point Financial Group, LLC 0.09% 19,000 $177K
18 nVerses Capital, LLC 0.09% 10,069 $94K
19 Virtus Investment Advisers, LLC 0.06% 25,154 $234K
20 ADAR1 Capital Management, LLC 0.06% 116,712 $1.1M
21 EntryPoint Capital, LLC 0.06% 21,602 $201K
22 ArrowMark Colorado Holdings LLC 0.05% 202,864 $1.9M
23 Rtw Investments, LP 0.04% 475,737 $4.4M
24 Kera Capital Partners, Inc. 0.03% 24,068 $224K
25 Perigon Wealth Management, LLC 0.02% 146,197 $1.4M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — 4d Molecular Therapeutics In (FDMT)

What does the Smart Money Trend signal show for FDMT?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their FDMT positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for FDMT?

More sellers than buyers — 46% buying: Last quarter: 79 funds reduced or exited vs 66 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for FDMT holders?

Strong quality — 38% AUM from major funds: 37 of 147 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held FDMT?

47% of holders stayed for 2+ years: 69 out of 147 hedge funds have held FDMT for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy 4d Molecular Therapeutics In (FDMT) following the 2026 Q1 hedge fund 13F filings?

As of today, FDMT has moved -3.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -9.5%. Since the quarter end (March 31, 2026), FDMT has gained -5.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →